A Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR(R)) and Atomoxetine (Strattera(R)) in School-Aged Children With Attention Deficit/Hyperactivity Disorder
Mixed amphetamine salts extended release (MAS XR; Adderall XRreg;) and atomoxetine (Stratterareg;) were compared in children 6 to 12 years old with attention deficit/hyperactivity disorder (ADHD) combined or hyperactive/impulsive type in a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study. Primary efficacy measure was the SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) behavioral rating scale. Changes in mean SKAMP deportment scores from baseline were significantly greater for MAS XR (n = 102) than for atomoxetine (n = 101) overall (-0.56 and -0.13, respectively; p lt; .0001) and at each week (p lt; .001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of ...
SCIENCE DIGEST: FDA: More warnings for ADHD drugs
The makers of Ritalin, Adderall, Strattera and other drugs treating attention deficit hyperactivity disorder were advised by the government Wednesday to give patients and their parents an additional warning that those medicines can cause serious psychiatric and heart problems, including sudden death. (Source: Life)
